title: Prevention of intestinal infection by glycomacropeptide.
abstract: The preventive effects of glycomacropeptide (GMP) against intestinal infection were investigated, and conjugates of GMP with xylooligosaccharide (XOS) and carboxymethyldextran (CMD) were prepared by the Maillard reaction to enhance the effect of GMP. The binding ability of GMP to intestinal pathogenic bacteria was evaluated by a binding assay with biotinylated bacteria. GMP showed the ability to bind to Salmonella enteritidis and enterohemorrhagic Escherichia coli O157:H7 (EHEC O157). This binding ability was decreased by a sialidase treatment and completely eliminated by periodate oxidation. These results indicate that such carbohydrate moieties as sialic acid in GMP are involved in binding to S. enteritidis and EHEC O157. The preventive effect of GMP on the adhesion of pathogenic bacteria to Caco-2 cells was also investigated. GMP showed an inhibitory effect on the adhesion of EHEC O157 in a dose-dependent manner, although it was not a potent inhibitor of the adhesion of Salmonella infection. However, in the case of Salmonella infection, GMP-XOS and GMP-CMD significantly suppressed IL-8 production which was the index of infection. Our results indicate GMP to be a promising agent for preventing intestinal infection.
authors.affiliation: Institute of Symbiotic Science and Technology, Division of Agriscience and Bioscience, Tokyo University of Agriculture and Technology, Japan.
authors.forename: Kouhei
authors.initials: K
authors.lastname: Nakajima
authors.forename: Norimitsu
authors.initials: N
authors.lastname: Tamura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kobayashi-Hattori
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Hara-Kudo
authors.forename: Masanari
authors.initials: M
authors.lastname: Ikedo
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Sugita-Konishi
authors.forename: Makoto
authors.initials: M
authors.lastname: Hattori
mesh_terms: D000900:Anti-Bacterial Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D001419:Bacteria / Q000378:metabolism; D001424:Bacterial Infections / Q000382:microbiology / Q000517:prevention & control*; D001710:Biotin / Q000378:metabolism; D018938:Caco-2 Cells; D002364:Caseins / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*; D002448:Cell Adhesion / Q000187:drug effects; D012085:Chymosin / Q000737:chemistry; D003911:Dextrans / Q000737:chemistry; D004591:Electrophoresis, Polyacrylamide Gel; D005658:Fungi / Q000187:drug effects / Q000378:metabolism; D006020:Glycopeptides / Q000138:chemical synthesis / Q000627:therapeutic use*; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis; D007410:Intestinal Diseases / Q000382:microbiology / Q000517:prevention & control*; D009181:Mycoses / Q000382:microbiology / Q000517:prevention & control*; D009844:Oligosaccharides / Q000737:chemistry
chemical_list: D000900:Anti-Bacterial Agents; D002364:Caseins; D003911:Dextrans; D006020:Glycopeptides; D016209:Interleukin-8; D009844:Oligosaccharides; C020251:kappa-casein glycomacropeptide; D001710:Biotin; C014392:carboxymethyl dextran; D012085:Chymosin